Final Results from Arq 197-209: A Global Randomized Placebo-controlled Phase 2 Clinical Trial of Erlotinib Plus ARQ 197 Versus Erlotinib Plus Placebo in Previously Treated EGER-inhibitor Naive Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Von Pawel, J. [1 ]
Akerley, W. [2 ]
Brugger, W. [3 ]
Ferrari, D. [4 ]
Garmey, E. [4 ]
Gerber, D. [5 ]
Orlov, S. [6 ]
Ramlau, R. [7 ]
Sequist, L. [8 ]
Schiller, J. [5 ]
机构：
[1] Asklepios Klinikum Gauting, Munich, Germany
[2] Univ Utah, Huntsman Canc Inst, Huntsman Canc Inst Canc Care Program, Salt Lake City, UT USA
[3] Schwarzwald Baar Clin, Schwenningen, Germany
[4] Ar Qule Inc, Woburn, MA USA
[5] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[6] St Petersburg Pavlov State Med Univ, St Petersburg, Russia
[7] Wielkopolskie Centrum Chorob Pluc & Gruzlicy, Poznan, Poland
[8] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2010年 / 5卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S501 / S501
页数：1
相关论文
共 50 条
  • [31] TOPICAL: Randomized phase III trial of erlotinib compared with placebo in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and unsuitable for firstline chemotherapy
    Lee, S.
    Rudd, R.
    Khan, I.
    Upadhyay, S.
    Lewanski, C. R.
    Falk, S.
    Skailes, G.
    Partridge, R.
    Ngai, Y.
    Boshoff, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] A RANDOMISED PLACEBO-CONTROLLED MULTICENTRE PHASE II TRIAL OF ERLOTINIB PLUS WHOLE BRAIN RADIOTHERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH MULTIPLE BRAIN METASTASES (TACTIC)
    Lee, Siow Ming
    Lewanski, Conrad
    Counsell, Nicholas
    Ottensmeier, Christian
    Bates, Andrew T.
    Patel, Nirali
    Wadsworth, Christina
    Ngai, Yenting
    Hackshaw, Allan
    Faivre-Finn, Corinne
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S298 - S299
  • [33] Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib
    Lara, Primo N., Jr.
    Longmate, Jeff
    Mack, Philip C.
    Kelly, Karen
    Socinski, Mark A.
    Salgia, Ravi
    Gitlitz, Barbara
    Li, Tianhong
    Koczywas, Mariana
    Reckamp, Karen L.
    Gandara, David R.
    CLINICAL CANCER RESEARCH, 2015, 21 (19) : 4321 - 4326
  • [34] Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer
    Reckamp, Karen L.
    Koczywas, Marianna
    Cristea, Mihaela C.
    Dowell, Jonathan E.
    Wang, He-Jing
    Gardner, Brian K.
    Milne, Ginger L.
    Figlin, Robert A.
    Fishbein, Michael C.
    Elashoff, Robert M.
    Dubinett, Steven M.
    CANCER, 2015, 121 (18) : 3298 - 3306
  • [35] Phase II pharmacodynamic trial of erlotinib in previously treated patients with advanced non-small-cell lung cancer (NSCLC):: Study results
    Felip, Enriqueta
    Rojo, Frederico
    Reck, Martin
    Heller, Astrid
    Klughammer, Barbara
    Maacke, Heiko
    Mocks, Joachim
    Brennscheidt, Ulrich
    Gatzemeier, Ulrich
    Baselga, Jose
    ANNALS OF ONCOLOGY, 2006, 17 : 235 - 235
  • [36] KRAS subset analysis from randomized phase II trials of erlotinib versus erlotinib plus sorafenib or pazopanib in refractory non-small cell lung cancer (NSCLC)
    Waterhouse, David Michael
    Stults, Dawn Michelle
    Daniel, Davey B.
    Griner, Paula L.
    Greco, F. Anthony
    Burris, Howard A.
    Hainsworth, John D.
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib
    Azuma, Koichi
    Hirashima, Tomonori
    Yamamoto, Nobuyuki
    Okamoto, Isamu
    Takahashi, Toshiaki
    Nishio, Makoto
    Hirata, Taizo
    Kubota, Kaoru
    Kasahara, Kazuo
    Hida, Toyoaki
    Yoshioka, Hiroshige
    Nakanishi, Kaoru
    Akinaga, Shiro
    Nishio, Kazuto
    Mitsudomi, Tetsuya
    Nakagawa, Kazuhiko
    ESMO OPEN, 2016, 1 (04)
  • [38] Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer
    Levy, Benjamin P.
    Giaccone, Giuseppe
    Besse, Benjamin
    Felip, Enriqueta
    Garassino, Marina Chiara
    Domine Gomez, Manuel
    Garrido, Pilar
    Piperdi, Bilal
    Ponce-Aix, Santiago
    Menezes, Daniel
    MacBeth, Kyle J.
    Risueno, Alberto
    Slepetis, Ruta
    Wu, Xiaoling
    Fandi, Abderrahim
    Paz-Ares, Luis
    EUROPEAN JOURNAL OF CANCER, 2019, 108 : 120 - 128
  • [39] MODULATION OF THE CYCLOOXYGENASE PATHWAY IS ASSOCIATED WITH EFFICACY IN A RANDOMIZED PHASE II TRIAL OF ERLOTINIB AND CELECOXIB OR PLACEBO IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Fishbein, Michael C.
    Gardner, Brian
    Milne, Ginder L.
    Koczywas, Marianna
    Cristea, Mihaela
    Dowell, Jonathan E.
    Wang, Hejing
    Figlin, Robert A.
    Elashoff, Robert M.
    Dubinett, Steven M.
    Reckamp, Karen L.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1094 - S1094
  • [40] Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer
    Gerber, David E.
    Socinski, Mark A.
    Neal, Joel W.
    Wakelee, Heather A.
    Shirai, Keisuke
    Sequist, Lecia V.
    Rosovsky, Rachel P.
    Lilenbaum, Rogerio C.
    Bastos, Bruno R.
    Huang, Chao
    Johnson, Melissa L.
    Hesketh, Paul J.
    Subramaniam, Deepa S.
    Dietrich, Martin F.
    Chai, Feng
    Wang, Yunxia
    Kazakin, Julia
    Schwartz, Brian
    Schiller, Joan H.
    Brahmer, Julie R.
    Kelly, Ronan J.
    LUNG CANCER, 2018, 117 : 44 - 49
12345